Rodman & Renshaw initiated coverage of Unity Biotechnology with a Buy rating and $8 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UBX:
- UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates
- Unity Biotechnology reports granting of employment inducement award
- Unity Biotechnology appoints Tozier as Chief Strategy Officer
- UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer